Structural simplification of N-n-alkylnicotinium analogs, antagonists at neuronal nicotinic acetylcholine receptors (nAChRs), was achieved by removal of the N-methylpyrrolidino moiety affording N-n-alkylpyridinium analogs with carbon chain lengths of C 1 to C 20 . 4
INTRODUCTION
Nicotine (Fig. 1 , Structure 1) activates neuronal nicotinic acetylcholine receptors (nAChRs), which are members of a ligand-gated ion channel family, consisting of transmembrane pentameric proteins with diverse composition (Le Novère et al., 2002) . Twelve genes encode α2-α10 and β2-β4 nAChR subunits, and in situ hybridization reveals their discrete, but overlapping, CNS distribution (Wada et al., 1989; Dineley-Miller and Patrick, 1992) . Individual neurons elaborate multiple nAChR subtypes, and more than two different subunits can assemble forming functional nAChRs (Forsayeth and Kobrin, 1997; Zoli et al., 2002) , greatly increasing the complexity of nAChR pharmacology. Thus, nAChR subtype diversity originates from differences in amino acid sequences of subunit proteins and from multiple combinations of subunit assemblies forming functional nAChRs. The exact subunit composition, stoichiometry and arrangement of native nAChRs remain to be elucidated (Lukas et al., 1999 (Whiting and Lindstrom, 1987; Flores et al, 1992) , and β2-knockout mice do not exhibit high affinity [ 3 H]nicotine binding .
Homomeric α7ÀÃ68uSÃirqÃiÃb (Davies et al., 1999) , are also abundant in brain (Wada et al., 1989; Flores et al., 1992) .
nAChRs are preferentially located presynaptically and modulate neurotransmitter release (McGehee and Role, 1995; Wonnacott, 1997) . nAChRs are located on the soma and terminals of substantia nigra dopamine (DA) neurons (Wonnacott, 1997) , and nicotine evokes DA release in striatum (Teng et al., 1997) . Subtype assignment of native nAChRs mediating nicotine-evoked DA release is based on several experimental approaches, including inhibition of agonist-induced response by subtypeselective nAChR antagonists, which are defined by inhibitory activity in cell systems expressing nAChR subunits of known composition, by results from studies using nAChR-subunit knockout mice, and by in situ hybridization and single cell PCR of mRNA in nigral neurons. Results from these current experimental approaches have generated considerable controversy regarding the exact subunit composition of nAChR subtypes mediating nicotine-evoked DA release (Klink et al., 2001; Azam et al., 2002; Champtiaux et al., 2002; Whiteaker et al., 2002; Zoli et al., 2002) , and great effort is focused currently on elucidating the specific nAChR subtypes involved in this response.
Increased understanding of the structural and functional diversity of nAChRs has stimulated great interest in the development of subtype-selective nAChR agonists; however, less attention has focused on development of subtype-selective nAChR antagonists (Dwoskin et al., 2000; Dwoskin and Crooks, 2001 ).
Pharmacophore geometries for antagonist binding sites are ill-defined, and very few subtype-selective nAChR antagonists are available currently. Notwithstanding the complexity and controversy concerning the composition of nAChR subtypes mediating nicotine-evoked DA release, the development of subtypeselective antagonists and the identification of antagonist pharmacophores at these nAChRs will provide an arsenal of pharmacological agents to further our understanding of subtype compositions mediating nicotine-evoked DA release, as well as unraveling the complexity of the effect of nicotine on this response. Additionally, these subtype-selective antagonists may find utility as therapeutic agents in the treatment of neurological diseases associated with cholinergic modulation of dopaminergic neurotransmission.
6 striatal membranes (Wilkins et al., 2002 (Wilkins et al., , 2003a (Wilkins et al., 2002 (Wilkins et al., , 2003a (Wilkins et al., , 2003b . Furthermore, these analogs do not exhibit affinity for α7* nAChRs, assessed using [ 3 H]MLA binding. Thus, NONI and NDNI are relatively selective and potent nAChR antagonists, but they act at different nAChR subtypes.
The purpose of the present study was to begin to elucidate the structural requirements for this class of N-n-alkylnicotinium nAChR antagonists. The initial strategy was structural simplification by removal of the N-methylpyrrolidino moiety to afford N-n-alkylpyridinium analogs ( which were assessed for their activity at α4β2* and α7* nAChR subtypes, and at nAChR subtypes mediating nicotine-evoked DA release.
MATERIALS AND METHODS
Chemicals. N-n-Alkylpyridinium analogs were synthesized via direct N-alkylation of pyridine utilizing the method of Ayers et al., (2002) . Structures of these N-n-alkylpyridinium analogs are shown in The procedures for the binding assay were a modification of a previously described method (Wilkins et al., 2003a) . Striatum was dissected, frozen and stored at -70°C. Striata from two rats were pooled and homogenized with a Tekmar polytron homogenizer (setting 40; Tekmar, Cincinnati, OH), in 10 volumes of ice-cold 20 mM Krebs-HEPES buffer, pH 7.5, containing 118 mM NaCl, 4.8 mM KCl, 2.5 mM CaCl 2 and 1.2 mM MgSO 4 . Homogenate was incubated at 37°C for 5 min, then cooled to 4°C, and subsequently centrifuged (25,000g for 20 min at 4°C). The pellet was resuspended in 10 volumes ice-cold Milli-Q water, incubated at 37°C for 5 min and centrifuged (25,000g for 20 min at 4°C). The previous incubation and centrifugation steps were repeated twice using 10 volumes of ice-cold 10% Krebs-HEPES buffer. The final pellet was stored in 10% Krebs-HEPES buffer at -70°C until assay. Upon assay, the final pellet was resuspended in 2.0 ml ice-cold Milli-Q water to obtain a final protein concentration of 150-200 µg/100 µl of membrane suspension, determined using the Bradford dye-binding method (Bradford, 1976) (Dwoskin and Zahniser, 1986; Teng et al., 1997; Wilkins et al., 2002) . Briefly, coronal striatal slices (500 µm thickness, 6-8 mg) were incubated in Krebs' buffer (containing 118 mM NaCl, 4.7 mM KCl, 1.2 mM MgCl, 1.3 mM CaCl 2 , 1.0 mM NaH 2 PO 4, 11.1 mM glucose, 25 mM NaHCO 3 , 0.11 mM L-ascorbic acid and 0.004 mM EDTA, pH 7.4, saturated with 95% O 2 /5% CO 2 ) in a metabolic shaker for 30 min at 34°C. Then, slices (6-8 slices/3 ml) were incubated with fresh buffer containing [ 3 H]DA (0.1 µM, final concentration) for an additional 30 min. After rinsing in fresh buffer, each slice was transferred to a superfusion chamber and superfused at a flow rate of 1 ml/min with Krebs' buffer saturated with 95% O 2 /5% CO 2 . Superfusion buffer contained 10 µM nomifensine (a DA uptake inhibitor) and 10 µM pargyline (a monoamine oxidase inhibitor). After 60 min of superfusion, three 5-min samples (5 ml/sample) were collected to determine basal overflow. Furthermore, each striatal slice was exposed to only one concentration of analog. Thus, a repeated measures design was utilized to determine analog-induced intrinsic activity and analog-induced inhibition of nicotine-evoked [ 3 H]DA overflow using striatal slices from a single rat; the effect of each analog was determined using a group of 5-6 rats. At the end of the experiment, slices were solubilized in 1.0 ml TS-2 tissue solubilizer, and the pH and volume of the solubilized samples were adjusted to those of the superfusate samples. Radioactivity was determined by liquid scintillation spectroscopy.
Another series of experiments determined the ability of mecamylamine (10 µM) to inhibit the intrinsic activity produced by a representative analog of this structural series, NDDPI, at a concentration (10 µM) found to produce significant intrinsic activity in the above experiments. Experiments were performed as described above except that after collection of the third basal sample, each striatal slice from an individual rat was superfused for 60 min in either the absence or presence of mecamylamine, which remained in the buffer throughout the experiment. Following 60 min of superfusion in the absence or presence of mecamylamine, NDDPI (10 µM) was added to the buffer, and 5-min superfusate samples were collected for a period of 60 min to determine mecamylamine-induced inhibition of NDDPI-evoked
A control striatal slice in each experiment was superfused for 60 min in the absence of mecamylamine, followed by superfusion with NDDPI (10 µM) to determine NDDPI-evoked total [ 3 H]DA overflow. Another control slice was superfused for the entire period in the absence of either mecamylamine or NDDPI. Thus, a repeated measures design was used, and the effect of NDDPI was determined using a group of 6 rats.
The mechanism of inhibition of NDDPI was determined by Schild analysis. In each experiment, the concentration-response for nicotine (1 nM -100 µM) was determined in the absence and presence of a single concentration of NDDPI using striatal slices from a single rat. NDDPI inhibition of the effect of nicotine was determined at 3 concentrations of NDDPI (0.1, 0.3 or 0.6 µM), based on the previously determined IC 50 value for NDDPI-induced inhibition of nicotine (10 µM)-evoked [ 3 H]overflow. Slices were superfused for 60 min with buffer containing pargyline and nomifensine. Subsequently, slices were superfused in the absence or presence of a single concentration of NDDPI, which remained in the buffer throughout the experiment. After 60 min of superfusion in the absence or presence of NDDPI, one of six concentrations of nicotine (1 nM -100 µM) was added to the buffer and superfusion continued for an additional 60 min. Each slice from a single rat was exposed to only one concentration of nicotine and one concentration of NDDPI. These experiments utilized a repeated measures design, such that the concentration-response for nicotine was determined using striatum from a single rat; and NDDPI concentration was a between-group factor. Tissue and superfusate samples were processed as previously described.
To assess the selectivity of NDDPI-induced inhibition of the effect of nicotine, the ability of analogs was also determined. Intrinsic activity of the C 10 -C 20 N-n-alkylpyridinium analogs was assessed during the 60-min period of superfusion with each analog prior to addition of nicotine to the superfusion buffer (Table 2) . Intrinsic activity was not observed for any of the analogs at concentrations ≤ 1.0 µM. 
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DISCUSSION
Structural simplification of a series of N-n-alkylnicotinium antagonists was achieved by removal of the N-methylpyrrolidino moiety, which afforded N-n-alkylpyridinium analogs with carbon chain lengths ranging from C 1 to C 20 . These N-n-alkylpyridinium analogs had generally greater water solubility than the respective N-n-alkylnicotinium analogs, which allowed for evaluation of longer chain compounds (C 15 and C 20 ) in the current study. N-n-Alkylpyridinium analogs had low affinity for This series of N-n-alkylpyridinium compounds was initially evaluated for intrinsic activity in the DA release assay (i.e., analog-induced [ 3 H]DA overflow). As in the N-n-alkylnicotinium series, relatively high concentrations of analogs with n-alkyl chain lengths greater than or equal to C 10 exhibited intrinsic activity in the DA release assay; however, in contrast to the N-n-alkylnicotinium analogs, intrinsic activity produced by the current series of analogs was not related to chain length (Wilkins et al., 2002; present results was observed only at a 40-fold higher concentration of 10 µM. As such, NDDPI exhibits 40-fold selectivity as an antagonist at nicotinic receptors mediating nicotine-evoked DA release relative to its action to intrinsically evoke DA release likely via a non-nicotinic receptor-mediated mechanism. With the exception of NPDPB, which exhibits similar selectivity to NDDPI, the remaining analogs exhibit 330-fold selectivity for the nicotinic receptor mediating nicotine-evoked DA release (IC 50 ~0.3 µM), whereas intrinsic activity (stimulation of DA release) was observed at relatively higher concentrations (100 µM).
Thus, the 40-330 fold separation between analog-induced inhibition of nicotine-evoked dopamine release and analog-induced intrinsic activity supports the contention that these compounds are relatively selective as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release.
The N-n-alkylpyridinium analogs completely inhibited the effect of nicotine in the DA release assay, with the exceptions of NEcPB (C 20 analog) and NPDPB (C 15 analog), both compounds exhibiting maximal inhibition of only ~50%. High concentrations (10-100 µM) of NPDPB produced significant amounts of intrinsic activity, which may have contributed to the observed incomplete inhibition of the effect of nicotine. However, only the high concentration (100 µM) of NEcPB elicited a small, but significant, amount of intrinsic activity. At lower concentrations (10 µM), NEcPB induced maximal inhibition and no intrinsic activity was observed. Thus, maximal incomplete inhibition was observed at a concentration of NEcPB eliciting no intrinsic activity. The Conus snail neurotoxin, α-conotoxin-MII (Fig. 1, Structure 5) , also has been shown to inhibit ~50% of the response to nicotine in the DA release assay (Kulak et al, 1997; Kaiser et al., 1998; Kaiser and Wonnacott, 2000) . Whether the latter observations indicate that NEcPB and α-conotoxin-MII act at the same nAChR subtype remains to be determined. α-Conotoxin-MII inhibits acetylcholine electrophysiological responses in Xenopus oocytes expressing α3/α6 and α6/α4 nAChRs containing either β2 or β4 subunits (Luetje et al., 1990; Cartier et al., 1996; Kuryatov et al., 2000) . Also, α-conotoxin-MII binds with high affinity to immunopurified α6β2* , implicating nAChR subtypes containing these two subunits as mediating this response. Furthermore, [ 3 H]-α-conotoxin-MII binding was eliminated in α6-knockout mice, but not in α3-knockout mice, suggesting an interaction with native α6-containing nAChRs (Champtiaux et al., 2002; Whiteaker et al., 2002) . Additionally, studies using β2-knockout mice also implicate β2-containing nAChRs in nicotine-evoked DA release Grady et al., 2002) . The fact that α-conotoxin-MII and NEcPB inhibited only 50% of nicotine-evoked DA release indicates that more than one subtype of nAChR is involved (Kulak et al, 1997; Kaiser et al., 1998; present results) . Since nigral neurons express α3-α7 and β2-β4 mRNAs (Wada et al., 1989; Deneris et al., 1989; Le Novere et al., 1996; Charpantier et al., 1998; Arroyo-Jimenez et al., 1999; Klink et al., 2001; Azam et al., 2002; , it is quite possible that a diversity of nAChR subunit combinations and subtypes are involved in this response. Evidence is emerging which suggests that different DA neurons in the nigra can be categorized based upon the expression of particular nAChR subtypes with varying compositions of nAChR subunits (Azam et al., 2002) . Although speculative at the current time, it may be that the expression of nAChR subtypes by dopaminergic neurons is a dynamic process, which is regulated in part by the history of the organism, including environmental exposure and drug experience. With respect to drug discovery, NEcPB is a small molecule, but appears to produce the same functional effect (i.e., ~50% maximal inhibition) as the relatively larger neuroactive peptide, α-conotoxin-MII. The discovery of NEcPB sets the precedence for the development of small, non-peptide molecules that are selective antagonists for a subset of nAChR subtypes mediating nicotine-evoked DA release.
In terms of structure-activity relationships, analogs in the current N-n-alkylpyridinium series required longer n-alkyl substituents (i.e., C 10 -C 20 ) compared to those in the respective N-nalkylnicotinium series (C 8 -C 12 ) to obtain a comparable affinity (IC 50 = 0.1-0.5 µM) for nAChRs mediating nicotine-evoked DA release from striatum. Furthermore, in the N-n-alkylnicotinium series, n-alkyl chain length was linearly related to nAChR affinity; whereas in the N-n-alkylpyridinium series, no such linear relationship was observed. In this respect, C 10 -C 20 analogs were equipotent in inhibiting nicotine-evoked DA release, whereas analogs with alkyl chain lengths of less than C 10 did not inhibit nicotine-evoked
Interestingly, the C 10 analog, NDPI, was a potent inhibitor (IC 50 = 0.13 µM) of nicotine-evoked DA release (present results). This is in marked contrast to the C 10 analog, NDNI, which had no inhibitory activity in the nicotine-evoked DA release assay (Wilkins et al., 2002) . In the latter study, NDNI was proposed to exhibit a unique conformation to explain its unusual pharmacological profile; this unique conformation is obviously not maintained in the NDPI structure, after removal of the N-methylpyrrolidino moiety.
Although it appears that the nature of the cationic head group and the size of the n-alkyl substituent are both important in establishing affinity for nAChR subtypes mediating nicotine-evoked DA release, the lack of a linear relationship in the C 10 -C 20 analogs of the N-n-alkylpyridinium series indicates that antagonist potency is insensitive to chain length within this 10-carbon range. Thus, the inhibitory effect of these C 10 -C 20 N-n-alkylpyridinium analogs may be more generally related to a common physicochemical property of these molecules rather than to their differences in chemical structure. Evidence indicates that high micromolar concentrations (30-100 µM) of nicotine activate α7* homomeric nAChRs to evoke DA release through an indirect mechanism of action, i.e., nicotine-induced stimulation of α7* nAChRs releases glutamate from glutamatergic terminals, which then indirectly releases DA from dopaminergic terminals . Furthermore, glutamate receptor antagonists have been reported to inhibit ~20-50% of nicotine-evoked DA release from striatal slices, but not from striatal synaptosomes , indicating that local circuitry within the striatal slice is sufficient to detect this indirect effect of nicotine on DA release. n indicates number of rats/analog.
Number in parenthesis indicates n-alkyl chain length for each analog.
TABLE 3
Concentration (IC 50 ) of N-n-alkylpyridinium analogs required to reduce nicotine-evoked [ 3 H]DA overflow from superfused rat striatal slices by 50%.
IC 50 values and 95% confidence intervals (CI) were derived from the sigmoid fits to the percent control transformed data shown in Fig. 2 .
Number in parenthesis indicates n-alkyl chain length for each analog. Nicotine a) R = n-octyl NONI b) R = n-decyl NDNI a) R = methyl NMPI X = I b) R = ethyl NEPI X = I c) R = n-propyl NPrPI X = I d) R = n-butyl NBuPI X = I e) R = n-pentyl NPPI X = I f) R = n-hexyl NHxPI X = I g) R = n-heptyl NHPI X = I h) R = n-octyl NOPI X = I i) R = n-nonyl NNPI X = I j) R = n-decyl NDPI X = I k) R = n-undecyl NUPI X = I l) R = n-dodecyl NDDPI X = I m) R = n-pentadecyl NPDPB X = Br n) R = n-eicosyl NEcPB X = Br 
